⌕
Ocular Therapeutix · OCUL · Nasdaq
Tenet 51 · Mixed
Compare
$6.02+0.17%At closeTenet 51 · Mixed
$6.02+0.01 (+0.17%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Ocular Therapeutix (OCUL) Institutional Ownership

13F filers reported holding 13.6% of Ocular Therapeutix (OCUL) shares as of Sep 30, 2026, across 94 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
13.6%
Sep 30, 2026
13F filers
94
quarter ended Sep 30, 2026
13F value
$229.1M
29.9M shares
Quarter's fund flow
Mild accumulation
13 new · 13 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (13 new · 30 increased · 27 reduced · 13 closed · 11 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 94 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Nov 6, 2026Sherif RiaddirectorAcquired · Grant / award28,000—↗
Nov 6, 2026Sherif RiaddirectorAcquired · Grant / award88,000Stock Option (Right to Buy)—↗
Oct 8, 2026Anderman ToddChief Legal OfficerDisposed · Open-market sale11,984$7.29↗
Oct 2, 2026Kaiser PeterChief Development OfficerDisposed · Open-market sale9,990$7.05↗
Oct 2, 2026Heier Jeffrey S.Chief Scientific OfficerDisposed · Open-market sale10,869$7.05↗
Aug 31, 2026Notman DonaldChief Operating OfficerDisposed · Open-market sale1,099$10.24↗
Aug 25, 2026Dugel PravinSee RemarksDisposed · Gift50,092—↗
Aug 25, 2026Dugel PravinSee RemarksAcquired · Gift50,092—↗
Aug 24, 2026Kaiser PeterChief Development OfficerDisposed · Open-market sale3,035$10.77↗
Aug 24, 2026Nayak SanjayChief Strategy OfficerDisposed · Open-market sale1,897$10.78↗
Aug 24, 2026Heier Jeffrey S.Chief Scientific OfficerDisposed · Open-market sale3,296$10.78↗
Aug 24, 2026Dugel PravinSee RemarksDisposed · Open-market sale21,649$10.77↗
Jun 16, 2026Dugel PravinSee RemarksDisposed · Gift50,092—↗
Jun 16, 2026Dugel PravinSee RemarksAcquired · Gift50,092—↗
Jun 10, 2026Warden Charles MdirectorAcquired · Grant / award14,000—↗
Jun 10, 2026Warden Charles MdirectorAcquired · Grant / award44,000Stock Option (Right to Buy)—↗
Jun 10, 2026Graves Adrienne LdirectorAcquired · Grant / award14,000—↗
Jun 10, 2026Graves Adrienne LdirectorAcquired · Grant / award44,000Stock Option (Right to Buy)—↗
Jun 10, 2026Robins Jason ShandChief Financial OfficerAcquired · Grant / award15,441—↗
Jun 10, 2026Robins Jason ShandChief Financial OfficerAcquired · Grant / award14,024Stock Option (Right to Buy)—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Ocular Therapeutix do institutions hold?

13F filers reported holding 13.6% of Ocular Therapeutix's shares as of Sep 30, 2026, across 94 filers.

How many 13F filers hold Ocular Therapeutix?

Ocular Therapeutix was held by 94 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.